Camtarkibart clinical trials
Also written 611.
How each study uses camtarkibart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the camtarkibart studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- 611
- 7
Studies by the year they started
10 studies that test it; most in 2024 (3)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test camtarkibart, phase 3 first.
- Sep 2027Evaluation of 611 in Chinese Children With Moderate to Severe Atopic Dermatitis(AD)Phase 3 · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Studies
Open first, then newest update. How each study uses camtarkibart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- Evaluation of 611 in Chinese Children With Moderate to Severe Atopic Dermatitis(AD)RecruitingPhase 3Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.NCT07767253Written as 611
- Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic DermatitisRecruitingPhase 3Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.NCT07042126Written as 611
- Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseRecruitingPhase 3Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.NCT07039669Written as 611
- Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic DermatitisCompletedPhase 1/2Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.NCT06324812Written as Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611)
- Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic DermatitisCompletedPhase 3Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.NCT06173284Written as 611
- A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal PolypsActive, not recruitingPhase 3Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.NCT06639295Written as 611
- Evaluation of 611 in Chinese Adults With Moderate to Severe Chronic Obstructive Pulmonary DiseaseCompletedPhase 2Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.NCT06099652Written as 611 300 mg Q2W
- A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal PolypsActive, not recruitingPhase 2Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.NCT05865496Written as 611
- Evaluation of 611 in Chinese Adult Patients With Moderate-to-Severe Atopic DermatitisCompletedPhase 1/2Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.NCT05641558Written as 611 150mg
- Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy VolunteersCompletedPhase 1Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.NCT04527718Written as 611
Given beside what is tested · 1 — camtarkibart is usual care or a partner of the new treatment
Codes
What other systems call camtarkibart · ClinicalTrials.gg INT018683
- UNII (FDA) ZET03UJ3LACAMTARKIBARTOne source FDA
- NCI Thesaurus C223276CamtarkibartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | ZET03UJ3LA | CAMTARKIBART | One source FDA |
| NCI Thesaurus | C223276 | Camtarkibart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.